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Sunitinib in the therapy of malignant 
paragangliomas: report on the 
efficacy in a SDHB mutation carrier 
and review of the literature
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SUMMARY
Metastatic pheochromocytomas (PHEOs) and paragangliomas (sPGLs) are rare neural crest-derived 
tumors with a poor prognosis. About 50% of them are due to germ-line mutations of the SDHB 
gene. At present, there is no cure for these tumors. Their therapy is palliative and represented by 
different options among which antiangiogenic drugs, like sunitinib, have been hypothesized to be ef-
fective especially in malignant SDHB mutated tumors. We report the effects of sunitinib therapy in a 
SDHB mutation carrier affected by a malignant sPGL. During 101 weeks of therapy at different doses, 
sunitinib was able to cause a partial response and then a stable disease for a total of 78 weeks. This 
favorable response is the longest, out of the 35 so far reported in the literature, registered in a patient 
treated exclusively with sunitinib but, similarly to the other responses, the effect was limited in time. 
From our analysis of the scanty data present in the literature, the effect of sunitinib does not seem 
to be different among wild-type patients and those carrying a cluster 1 germ-line mutation. Sunitinib 
seems able to slow the disease progression in some patients with malignant PHEO/PGL and therefore 
may represent a therapeutic option, although randomized controlled studies are needed to assess 
its efficacy definitively in the treatment of these aggressive tumors. Arch Endocrinol Metab. 2017;61(1):90-7
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P heochromocytomas (PHEOs) and paragangliomas (PGLs) are neural crest-derived tumors (1). 
They are benign in about 90% of cases. Malignancy 
is diagnosed in the presence of metastases in organs 
devoid of chromaffin tissue such as bones, lymph 
nodes, liver and lungs.
Malignancy rate mostly depends on genetic 
background; about 50% of malignant PHEO/PGL are 
due to a germ-line mutation in the SDHB gene (2-3).
Patients with benign PHEOs/sPGLs are cured by 
the surgical removal of the tumor while the treatment 
of malignant PHEOs/PGLs is palliative and aimed at 
prolonging patient survival and/or improving patient’s 
quality of life (4). In the presence of a metastatic 
PHEO/PGL, 5 year survival is about 50% (5-7). 
Treatment of patients with malignant PHEOs/
sPGLs stems on several options: surgery, when 
feasible, is generally performed on the primary tumor 
and is mostly aimed at limiting the effects of high 
levels of catecholamines on target organs and, if 
radionuclide therapy is programmed, at enhancing 
I131-metaiodobenzylguanidine (MIBG) uptake by the 
remaining metastatic lesions (8). Radionuclide therapy 
using somatostatin analogs tracers has seldom proven 
to be effective (9). Chemotherapy has been employed 
mostly in progressive disease, with partial success, 
combining different drugs such as cyclophosphamide, 
vincristine and dacarbazine (CVD) (10) or with the 
alkylating drug temozolomide causing stable disease in 
up to 50% of the cases (11).
More recently other compounds have been 
proposed. Among these, drugs such as sunitinib have 
been hypothesized to be effective in SDHB mutated 
PGL in view of their genetic profile, characterized by an 
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In this paper, we report on the effect obtained by 
sunitinib, administered as monotherapy, in a SDHB 
mutation carrier affected by a metastatic PGL and 
review the literature reporting the response to sunitinib 
in similar cases. 
CASE REPORT
A 35 year old Caucasian male with a metastatic 
abdominal paraganglioma was referred to our Unit in 
September 2013. The patient, presenting a congenital 
right kidney hypoplasia, had already undergone surgery 
twice: at the age of 10 years, when a PGL localized near 
the left kidney was surgically removed, and at the age of 
31 when he was operated for a local recurrence.
In 2012 he started presenting symptoms of 
catecholamine excess like hypertensive crises, palpitations 
and headache. At that time, urinary normetanephrine 
(NMNu) was reported to be elevated. A 18FDG-PET 
showed persistent disease at the primary site and uptake 
in the left ischium. A I123MIBG scintigraphy resulted 
positive only at the bone level. A 111-In-Pentetrotide 
scan (Octreoscan) showed a low density of somatostatin 
receptors.
In September 2013, at admission, the laboratory 
tests showed a very high level of NMNu (8927 
mcg/24h). A CT scan showed a new large abdominal 
recurrence 46x49x59 mm in size, located in the 
left lumbar-aortic region, other smaller abdominal 
peritoneal lesions (maximum diameter 20 mm) as well 
as several liver metastases.
A 99Tc-diphosphonate bone scintigraphy resulted 
negative.
After written informed consent the patient underwent 
genetic testing, including all the major susceptibility 
genes. A heterozygous G>A transversion variant at 
position +1 of intron 4 was found in the SDHB gene.
Despite doxazosine therapy at the dose of 2 mg/
day, the patient blood pressure resulted 140/105 
mmHg. Therefore, doxazosin dosage was progressively 
increased until normotension was obtained.
In October 2013, compression of the left ureter 
by the abdominal mass caused hydronephrosis and a 
sharp increase in serum creatinine (2.40 mg/dL). The 
obstruction was resolved by a pigtail insertion. 
After two months (November 2013, t0), without 
any anticancer therapy, a CT scan showed a significant 
increase in size of the main lesion (69x56x77 mm) 
(Figure 1B). NMNu resulted further increased (10147 
mcg/24h) (Figure 2). In view of a disease progression 
(PD), the patient started Sunitinib therapy. 
Disease progression was evaluated during the 
follow up by RECIST criteria (version 1.1) (14). The 
main abdominal recurrence was considered the target 
lesion.
Sunitinib doses and time schedules are reported 
in Figure 3. Both time schedules and doses were in 
time adjusted to the maximal time length and drug 
doses accepted by the patient, depending on the drug 
induced side effects (Table 1). 
In February 2014 (t1), at first follow up, a partial 
response (PR) as documented by a reduction in size 
of the main abdominal lesion (37x35x36 mm) and the 
other abdominal and liver metastases (Figure 1C), as 
well as a significant decrease in NMNu levels (5572 
mcg/24h) were found (Figure 2). The 18FDG-PET scan 
showed a reduction in the uptake of the liver metastases 
and in the number and uptake of the abdominal lesions. 
The uptake in the main abdominal lesion didn’t change 
significantly (Figure 4B). 
In July 2014 (t2), after additional 5 months of 
therapy, the disease was found stable at CT (main 
abdominal lesion: 37x38x36 mm) (SD) (Figure 1D) 
and 18FDG-PET (Figure 4C) while NMNu levels 
continued to decline (3276 mcg/24h) (Figure 2). 
At the third follow up in December 2014 (t3), the 
main abdominal lesion was further decreased in size 
(27x34x34 mm) while the other abdominal lesions and 
the liver metastases resulted unchanged (Figure 1E).
The 18FDG-PET scan showed a lower uptake of liver 
metastases and no change in the bone lesion (Figure 4D). 
The levels of NMNu were 1907 mcg/24h (Figure 2). 
In May 2015 (t4), at the fourth follow up, the patient 
presented PD on CT (Figure 1F) and 18FDG-PET 
(Figure 4E). The main abdominal lesion had increased 
in size (51x38x60 mm) and two new peritoneal 
lesions appeared while the liver metastases resulted 
unchanged. According to these findings, NMNu was 
found increased to 9250 mcg/24h (Figure 2).
In October 2015 (t5), after almost two years of 
therapy with Sunitinib, we observed a further increase in 
the size (62x50x75 mm) of the main abdominal lesion 
and in the number of liver metastases (Figure 1G) lately 
confirmed by 18FDG-PET (Figure 4F). 
To date the patient has completed 101 weeks of 
therapy and has PD, according to the RECIST criteria 
1.1. He’s continuing Sunitinib therapy at low doses 
(25 mg/day 2 weeks on, 1 week off) with limited side 
effects. Radiosurgery on the primary tumor and the 
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Figure 1. CT scan before sunitinib therapy: Sept. ’13 (A) and Nov.’13 (B), and during the follow up: t1 (C), t2 (D), t3 (E), t4 (F) and t5 (G). In the first line 
the main abdominal lesion, in the second line another abdominal lesion and in the third line liver metastases. 
Sep. ‘13 Nov. ’13 (t0) Feb. 2014 (t1) Jul. 2014 (t2) Dec. 2014 (t3) May. 2015 (t4) Oct. 2015 (t5)
Figure 2. Trend of urinary normetanephrine (NMNu) combined with the size of tumor recurrence (mm).
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Figure 4. 18FDG-PET before (A) and during (B-F) sunitinib therapy.
Nov. 2013 (t0) Feb. 2014 (t1) Jul. 2014 (t2) Dec. 2014 (t3) May. 2015 (t4) Oct. 2015 (t5)
Table 1. Side effects evaluated by the Common Toxicity Criteria Manual version 2.0. Grade 0 no adverse event or within normal limits; grade 1 mild 
adverse event; grade 2 moderate adverse event; grade 3: severe and undesirable adverse event; grade 4 life-threatening or disabling adverse event; 
grade 5 death related to adverse event
Side effects Drugs Grades of adverse events
Fatigue - 3
Stomach pain with nausea and vomiting Ranitidine and ondansetron 3
Hypothyroidism Levothyroxine 1
Hypertriglyceridemia ω 3 and fenofibrate 2
Hypertension Doxazosin, calcium antagonist 2
Sore mouth Mouthwash with aloe or baking soda 3
DISCUSSION
In this paper we report the long lasting effect of 
sunitinib in a patient affected by a metastatic PGL. The 
surgical option on the primary lesion was discarded in 
view of the congenital right renal hypoplasia and the 
close adhesion of the tumor mass to the left kidney and 
ureter causing a high risk of postsurgical chronic renal 
failure. Radionuclide therapy with radiolabeled MIBG 
(15) or somatostatin analogs (16) was impeded by the 
insufficient uptakes of both the compounds. Therefore, 
we decided to start medical therapy using sunitinib. 
Sunitinib is an oral tyrosine kinase inhibitor that 
targets the signaling pathways of VEGF receptors 1 and 
2, PDGF-β receptor, and other tyrosine kinases (c-KIT, 
FLT3, and RET) (17).
The therapy schedule recommended in the 
treatment of advanced renal cell carcinoma or 
gastrointestinal stromal tumors is 50 mg/day 4 weeks 
on and 2 weeks off (21), but it is generally accepted 
to adapt it to patient’s tolerability. Therefore, in time, 
we reduced the doses and changed the drug schedule 
according to the side effects, mainly gastric pain and 
sore mouth, that the patient complained of. Thus, 
during the treatment, the patient’s performance 
status was maintained grade 2 according to ECOG 
performance status criteria (18). 
After an initial PD in the absence of therapy, 
Sunitinib caused a PR, as evaluated by RECIST criteria, 
lasting 3 months followed by a period of SD lasting 10 
months. 
In the following 12 months, we observed a slight 
progressive increase in the sizes of the primary lesion 
that nevertheless were still lower than those measured at 
the start of sunitinib administration (69 mm vs 62 mm). 
As a whole, sunitinib slowed the disease progression in 
the last two years, allowing the patient to have a fairly 
good quality of life. It is also possible that the slight 
progression observed in the last 12 months might 
depend on the reduction in the drug doses, decided to 
limit its side effects.
To our knowledge, at present, only other 35 patients 
affected by a malignant PHEO/sPGL and treated with 
sunitinib have been reported in the literature (12-
13,18-28). Their characteristics, as well as those of our 
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Table 2. Summary of the literature review. 








Treatment Wk of 
therapy
Outcome
Park KS and 
cols., 2009 
M (17 yr) PHEO NA Yes 37,5 mg/day for 7 weeks and 25 mg/
day for 4 weeks
11 PR* after 7 weeks  (according to 
18FDG uptake) followed by SD* 
after 11 weeks
Jimenez C and 
cols., 2009
F (32 yr) PHEO  
(10.5 cm)
VHL Yes 50 mg/day 4 weeks on, 2 weeks off 36 PR*
Joshua AM and 
cols., 2009 
M (55 yr) Abdominal 
PGL  
(14.4 cm) 
SDHB No (after 
six cycles)
50/mg day 4 weeks on, 2 weeks off 
(before surgery); 37.5 mg/ day 4 weeks 
on, 2 weeks off (after surgery)
48 PR after 36 weeks followed by PD 
after 48 weeks (+ surgery)
  M (28 yr) Abdominal 
PGL (7 cm)
SDHB Yes 50/mg day 4 weeks on, 2 weeks off** 40 PR






Yes 50 mg/day 4 weeks on, 2 weeks off** 40 PR*
Hahn NM and 
cols., 2009
F (33 yr) Abdominal 
PGL (17 cm)
SDHB Yes 50 mg/day 4 weeks on, 2 weeks off;  
50 mg/day 2 weeks on, 1 week off
16 PD*
Cirillo F, 2010 M (37 yr) Abdominal 
PGL 
(17x14x9 cm)
NA Yes 50 mg/day 4 weeks on, 2 weeks off;  
25 mg/day 4 weeks on, 2 weeks off;  
25 mg/day 2 weeks on, 1 week off
24 SD* after 15 weeks followed by 










Yes 50 mg/day 4 weeks on, 2 weeks off 24 SD* after 12 weeks followed by 
PD* after 24 weeks
  F (54 yr) PHEO Sporadic Yes 50 mg/day 4 weeks on, 2 weeks off 
reduced up to 12.5 mg/day 
68 SD* after 40 weeks followed by 
PD* after 68 weeks
Ayala-Ramirez M 
and cols., 2012 F 
(8); M (9)
(33 yr) PHEO VHL No 50 mg/day 4 weeks on,  2 weeks off or 
37.5 mg/day continously or 37.5 mg/
day 3 weeks on, 1 week off
24 SD
  (60 yr) PHEO Sporadic No 50 mg/day 4 weeks on,  2 weeks off or 
37.5 mg/day continously or 37.5 mg/
day 3 weeks on, 1 week off
44 PR
  (55 yr) PGL SDHB No 50 mg/day 4 weeks on, 2 weeks off or 
37.5 mg/day continously or 37.5 mg/
day 3 weeks on, 1 week off
108 SD
  (20 yr) PGL SDHB No 50 mg/day 4 weeks on,  2 weeks off or 
37.5 mg/day continously or 37.5 mg/
day 3 weeks on, 1 week off
NA SD
  (62 yr) PHEO Sporadic No 50 mg/day 4 weeks on,  2 weeks off or 
37.5 mg/day continously or 37.5 mg/
day 3 weeks on, 1 week off
 1.6 PD
  (14 yr) PHEO Sporadic No 50 mg/day 4 weeks on, 2 weeks off or 
37.5 mg/day continously or 37.5 mg/
day 3 weeks on, 1 week off
13 PD
  (47 yr) PHEO Sporadic No 50 mg/day 4 weeks on, 2 weeks off or 
37.5 mg/day continously or 37.5 mg/
day 3 weeks on, 1 week off
16 PD
  (40 yr) PHEO Sporadic No 50 mg/day 4 weeks on, 2 weeks off or 
37.5 mg/day continously or 37.5 mg/
day 3 weeks on, 1 week off
4 PD
  (57 yr) PGL SDHB No 50 mg/day 4 weeks on, 2 weeks off or 
37.5 mg/day continously or 37.5 mg/
day 3 weeks on, 1 week off
NA NA (sunitinib was stopped due to 
toxicity)
  (60 yr) PGL SDHB No 50 mg/day 4 weeks on, 2 weeks off or 
37.5 mg/day continously or 37.5 mg/
day 3 weeks on, 1 week off
NA NA (sunitinib was stopped due to 
toxicity)
  (69 yr) PHEO Sporadic No 50 mg/day 4 weeks on, 2 weeks off or 
37.5 mg/day continously or 37.5 mg/
day 3 weeks on, 1 week off
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  (27 yr) PHEO SDHB No 50 mg/day 4 weeks on, 2 weeks off or 
37.5 mg/day continously or 37.5 mg/
day 3 weeks on, 1 week off
NA SD
  (56 yr) PHEO Sporadic No 50 mg/day 4 weeks on, 2 weeks off or 
37.5 mg/day continously or 37.5 mg/
day 3 weeks on, 1 week off
48 PR
  (45 yr) PGL SDHB No 50 mg/day 4 weeks on, 2 weeks off or 
37.5 mg/day continously or 37.5 mg/
day 3 weeks on, 1 week off
18 PR
  (40 yr) PGL SDHB No 50 mg/day 4 weeks on, 2 weeks off or 
37.5 mg/day continously or 37.5 mg/
day 3 weeks on, 1 week off
32 SD
  (43 yr) PHEO SDHB No 50 mg/day 4 weeks on, 2 weeks off or 
37.5 mg/day continously or 37.5 mg/
day 3 weeks on, 1 week off
16.4 PD
  (63 yr) PHEO Sporadic No 50 mg/day 4 weeks on, 2 weeks off or 
37.5 mg/day continously or 37.5 mg/
day 3 weeks on, 1 week off
8.4 PD
Nemoto K and 
cols., 2012 
F (41 yr) PHEO  
(10 cm)
NA Yes 50 mg/day 4 weeks on, 2 weeks off; 25 
mg/day 2 weeks on, 2 weeks off
26 PR
Sun FK and 
cols., 2012






Yes 50 mg/day 4 weeks on, 2 weeks off; 
37.5 mg/day 4 weeks on, 2 weeks off
22 Enlargement in the necrosis area 
of tumor with SD*






Yes 50 mg/day 4 weeks on, 2 weeks off 28 Necrosis of the lesions at the CT 
scan (PR*)






Yes 50 mg/day 4 weeks on, 2 weeks off 30 PR*
Prochilo T and 
cols., 2012
F (35 yr) Abdominal 
PGL
SDHB Yes 50 mg/day 4 weeks on, 2 weeks off; 
37.5 mg daily 2 weeks on, 2 weeks off; 
25 mg daily 2 weeks on, 1 week off
More 
than 36
PR* after 12 weeks followed by 
SD* after 36 weeks and finally 
PD* (evaluated by 18FDG-PET)
Hata J and cols., 
2014 
M (23 yr) PHEO  
(8.7 cm) 
NA Yes 50 mg/day 4 weeks on, 2 weeks off 20 SD (the authors not reported how 
many weeks after) followed by 
PD* after 20 weeks
  M (60 yr) PHEO  
(7.2 cm)
NA Yes 50 mg/day 4 weeks on, 2 weeks off** 16 SD* (the authors not reported how 
many weeks after) followed by 
PD* after 16 weeks
Lebowitz-Amit R 
and cols., 2014 









Yes 50 mg/day; 37.5 mg/day; 25/37.5 mg/
day alternating 
24  SD*
Bourcier ME and 
cols., 2013
F (70 yr) Abdominal 
PGL
NA Yes 50 mg/day 4 weeks on, 2 weeks off 12 CR
Our case M (35yr) Abdominal 
PGL
SDHB yes 25 mg/day 2 weeks on, 1 week off for 
the of time
101 PR after 12 weeks followed by SD 
after 32 weeks up to 54 weeks 
and PD after 78 weeks
F: female; M: male; NA: not available; PGL: paraganglioma; PHEO: pheochromocytoma; * data deducted by the case description and not by RECIST evaluation; ** deducted data. Weeks are always 
reported from the beginning of sunitinib therapy.








Treatment Wk of 
therapy
Outcome
In this series 20 patients were males and 16 females, 
aging from 14 to 70 yrs.
Genetic analysis was performed in 30 out of 36 
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Lindau (VHL) mutation carriers and 13 SDHB 
mutation carriers. Therefore, a SDHB germ-line 
mutation was found in 43.3% (13/30) of genotyped 
patients, in agreement with the high frequency of 
malignancy reported in SDHB mutation carriers (29). 
Surgery on the primary tumor had been carried out 
in 50% of patients (18/36). Sunitinib was administered 
as first non surgical therapy in 33% (12/36). 
The length of sunitinib therapy has been reported 
in 31/36 patients and ranges from 16 to 108 weeks.
The outcome of sunitinib therapy has been 
reported according to different criteria: in 19 patients 
the outcome has been calculated by RECIST criteria 
while in 14 patients the outcome has been reported by 
unspecified criteria. In 3 patients the outcome was not 
reported as the treatment was interrupted shortly after 
the start of therapy because of drug toxicity.
As a whole, 7 patients experienced PD, while 
sunitinib resulted effective in 72.2% of patients (26/36), 
providing a complete response (CR) in 1 patient, a PR 
in 13 patients and a SD in 12 patients. 
CR was observed after 12 weeks. In all patients 
(13/13) with PR the length of therapy is reported and 
the drug effect was maintained after a period ranging 
from 11 to 101 weeks. In this group, PD latterly ensued 
in 3 patients, after 48, more than 36 and 78 weeks from 
the beginning of therapy. 
Among the 12 patients found with SD the length 
of therapy was reported in ten of them, ranging from 
16 to 108 weeks and 5 were reported to undergo PD 
at different times after the beginning of therapy (from 
16 to 68 weeks).
It has been hypothesized that the genetic 
background might affect the effects of antiangiogenic 
therapy, resulting more effective in PHEO/PGL 
belonging to cluster 1 (30).
When analyzing this series reported in the literature, 
among the 30 genotyped patients, the outcome 
was reported in 14 wild type (wt) patients and in 13 
mutation carriers (11 SDHB and 2 VHL). PR or SD was 
reported in 9 wt and 11 mutated patients, respectively. 
Therefore, at least from this limited series, the different 
genetic background does not seem to affect sunitinib 
efficacy.
In summary, from the scant data of the literature, 
sunitinib seems able, in some patients, to slow the 
progression of the disease and its efficacy does not 
seem to depend on tumor genetic background. 
Nevertheless, its real efficacy will be stated only after 
the results of proper controlled studies. At present, 
only two such studies are ongoing in patients with 
malignant PHEOs/sPGLs: the FIRSTMAPPP study 
(First International Randomized Study in Malignant 
Progressive Pheochromocytoma and Paraganglioma) 
and the SNIPP study (Study of Sunitinib in Patients 
with Recurrent Paraganglioma/Pheochromocytoma). 
Both are Phase II studies. 
FIRSTMAPPP is a multicenter and randomized 
study (sunitinib 37.5 mg/day versus placebo) while 
SNIPP is a non randomized study (sunitinib 50 mg/
day 4 weeks on, 2 weeks off). 
In conclusion, we describe the case of a patient with 
malignant PHEO treated only with sunitinib for a very 
long period (101 weeks). The drug was able to induce 
a PR after 12 weeks and to maintain its effects (SD) 
for an additional 66 weeks. In spite of a slow disease 
progression, at present the patient still presents a good 
quality of life. Because of PD, the patient has started 
treatment with Temozolomide.
The results we observed in our patient are similar 
to those reported in other patients similarly affected by 
malignant PHEO/PGL. As a whole, sunitinib seems 
to offer a therapeutic option in some of these patients, 
although its effect seems limited in time.
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